Current Report Filing (8-k)
December 12 2022 - 08:41AM
Edgar (US Regulatory)
0001782107 false 0001782107 2022-12-12
2022-12-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported):
December 12, 2022
Blue Water Vaccines Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-41294 |
|
83-2262816 |
(State
or other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
|
201 E. Fifth Street,
Suite
1900
Cincinnati,
Ohio |
|
45202 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s telephone number, including area code: (513)
620-4101
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on Which Registered |
|
Common Stock, par value $0.00001 per share |
|
BWV |
|
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
Item 7.01 Regulation FD Disclosure.
On December 12, 2022, Blue Water Vaccines Inc. (the “Company”)
issued a press release announcing its first equity analyst coverage
since going public in February 2022, with the initial
recommendations as “buy” from each of Maxim Group LLC and H.C.
Wainwright & Co. A copy of the press release is attached hereto
as Exhibit 99.1.
The foregoing (including Exhibit 99.1) is being furnished pursuant
to Item 7.01 and will not be deemed to be filed for purposes of
Section 18 of the Securities and Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise be subject to the liabilities of
that section, nor will it be deemed to be incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the
Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
| |
Blue
Water Vaccines Inc. |
| |
|
|
| Date:
December 12, 2022 |
By: |
/s/
Joseph Hernandez |
| |
|
Joseph Hernandez |
| |
|
Chief
Executive Officer |
2
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Apr 2023 to May 2023
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From May 2022 to May 2023
